We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Innovaderma Plc | LSE:IDP | London | Ordinary Share | GB00BT9PTW34 | ORD EUR0.10 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 29.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
17/1/2017 22:54 | In addition why didn't they include figures on like-for like sales - based on the previous number of retail points? Actually I think we all know the answer to that. | allstar4eva | |
17/1/2017 22:45 | These BB's are incredible and fascinating in equal measure. The "Rampers" here - me included - anticipated and expected a stellar update! Retail points went from 250 - 2500! 1000% increase! Then there was the U.S launch, the full superdrug rollout, product selling out at numerous locations - there was good reason to be positive. We had every right to expect a large increase in sales - not 1000% of course but 150% at least. However the update was poor therefore previously positive holders have changed their stance - this is what happens - you take a position based on news flow unfortunately however the news was poor. There is no denying that - look at the share price reaction!!!! What absolutely stuns me is that despite the share price fall people still believe it was a great update! The company had been very bullish - yet the update was far from bullish therefore there are now trust issues which means that this stock will be traded but I'm not sure it will attract many new investors until confidence is restored. Having said that this could still come good - I am not bashing - just telling it how it is. For me the risks are now greater - it is now a hope rather than an expectation of future success which is why I sold yesterday - of course it was easier to sell when I got in below £1 but the story has changed for the worse. It may recover in time - there could be stellar news issued tomorrow re: FDA approval etc but at this point in time personally I am happy to give it a miss. | allstar4eva | |
17/1/2017 22:03 | Boffster. Just maybe, the decline in revenues is a seasonal issue. It will be interesting to see what the Jan - Jun '17 figures come in at, so a direct comparison of progress can be made. | markiemark321 | |
17/1/2017 22:02 | "Repeating a fact for the last 2 days." It's getting boring. "Lose what, exactly? I've not a penny invested here anymore." So why are you so active here? you will lose in bigger scheme of things as you have wrong intent. "Is it not a fundamental of a 'growth' company that revenues grow?" This company is in its infancy. The fact that it is already making profit is quite remarkable really. Give it a couple more years. "Every man and his dog are trying to find a male pattern baldness miracle cure. Most with far deeper pockets than IDP. Laser treatment is nothing new" FDA approval will carry a big marketing value, several million OOM. "Can't be all that smart!" you are only judging by very short term. Let's see the share price in 6 -12 months time. Tuck away mate. Illiquidity and uncertainty is causing volatility. ALways the case with new starters. Wait till the build is complete. Be patient. | andyr42 | |
17/1/2017 21:31 | 800+80+50+40+30+20 not a totally unreasonable growth projection for percentage of revenue growth. By my crude maths thats roughly 47 times revenenue increase in 6 years. Forgive me if i'm wrong or being far too bullish. Good luck all | thelongandtheshortandthetall | |
17/1/2017 21:17 | This highlights potential problems for small growing Companies... | ny boy | |
17/1/2017 20:05 | According to Kerastem’s analysis the annual hair loss market size is circa $7bn growing at a CAGR of 4.8%, with roughly a third of the market being accounted for by topical treatments. IDP is targeting FDA approval and product launch of the "Headmaster" helmet in H2 2017. There are competitors but many are not FDA registered and the Headmaster is being positioned as the first FDA registered product at an affordable price. Prices for the closest competitor in the US start at $895. IDP will be relaunching and enhancing its range of consumable ‘wet products’ that supplement the devices. These comprise high quality hair and scalp topical products which promote hair volume, scalp and hair condition and in the case of Leimo Instant Hair fibres that bond to existing hair and instantly give thinning hair the boost of fuller looking hair in seconds. The wet products are designed to provide a high level of recurring revenues with the helmet acting as something of a Trojan horse in terms of capturing a loyal customer base. As a result of exclusive agreements with major distributors to create a comprehensive, world-wide distribution network for Leimo, IDP is well positioned to pursue its target markets once the refreshed product range is launched. IDP's Leimo hair treatments already have customers in some forty countries. | goboy1 | |
17/1/2017 19:56 | It's a growth company in the early stages with a very small amount of shares so very illiquid, hence the big share price moves. Not for widows and orphans, but anyone buying here will make money in the medium to long term guaranteed. The hair restorer machine looks a load of carp but it's Skinny Tan that is the company maker. | zagrosfold | |
17/1/2017 19:44 | Edit. Re read carefully the post, so post withdrawn ! | luminoso | |
17/1/2017 19:38 | So revenues for the first 6 months of the current reporting year are already over 70% of the revenues for the entire previous 12 months. Revenues are infact accellerating compared to last year. | goboy1 | |
17/1/2017 19:27 | Its all academic anyway now because I presume they will present future accounts in £ sterling as they are now listed on the main London Stockmarket, manufacturing most of the stock in the UK, and the UK market for their products is bigger than the Australian market. | goboy1 | |
17/1/2017 19:25 | i.e. Revenues 6 months to 31/12/2016 = AU $5.93m= £3.0m (IDP, 16/1/2016) 12 months to 30/6/2016 = AU $8.3m = £4.2m (IDP 10/10/2016, incl. conversion rate AU$ to £ used in press release) 12 months 30/6/2015 = AU $1.05m = £0.525m (IDP, 10/10/2016, incl. conversion rate AU$ to £ used in press release) | goboy1 | |
17/1/2017 19:20 | For one thing if you convert £3.0m (Jul - Dec 2016) to AU $ using the same conversion rate used in the 10/10/2016 press release you will see £3.0m = AU $5.93m, whereas you have indicated AU $4.92, i.e. you have undercalculated July - Dec 2016 revenues by AU $1m ! i.e. If AU $8.3m = £4.2m for the 12 months to 30/6/2016 (IDP's own conversion) Then £3.0m = (3 / 4.2) x 8.3 = AU $5.928m for 6 months Jul - Dec 2016 | goboy1 | |
17/1/2017 19:11 | And? Why has revenue dropped? Are you saying my figures are wrong? If so, explain how | boffster | |
17/1/2017 19:08 | hottingup 17 Jan '17 - 15:45 - 2015 of 2047 0 1 boffster Revenues 6 months to 31/12/2016 = £3.0m (IDP, 16/1/2016) 12 months to 30/6/2016 = AU $8.3m = £4.2m (IDP 10/10/2016, incl. conversion rate AU$ to £ used in press release) 12 months 30/6/2015 = AU $1.05m = £0.525m (IDP, 10/10/2016, incl. conversion rate AU$ to £ used in press release) Trading update for the six months ended 31 December 2016 "The Board is pleased to announce that the Group's first half year financial performance has been encouraging and revenues are expected to show growth of just over 80% year-on-year on a constant currency basis to approximately GBP3.0 million (unaudited). The increase in revenue has been driven by......." | goboy1 | |
17/1/2017 18:49 | Revenue (approximate) over the last three 6-month periods, in Aussie dollars, calculated from the published numbers: - Jul - Dec '15 - $2.73m Jan - Jun '16 - $5.67m Jul - Dec '16 - $4.92m The decline in the latest half vs. the prior half being a cause for concern. Flying in the face of the upbeat company statements. | boffster | |
17/1/2017 17:47 | bookbroker, I have corrected, 248.5p, second last trade I think it was. | che7win | |
17/1/2017 17:46 | Which Friday was that, has been knowhere near 146p since 2016! What are you talking about? | bookbroker | |
17/1/2017 17:44 | I see both sides here. I bought from 75p all the way up to 146p. I spotted an enormous opportunity. I sold the 75p ones on Friday at 248.5p, Monday morning I exited the rest between 220p and 192p based on the update. I guess the market was aligned to that view. It always pays to listen to the contrarian view, and it is expected that news will change an opinion. It changed mine, but really its down to the valuation here for me. The potential is there, but the product will be successful on the marketing and that needs money. I expect profits will be eaten into by the costs of listing and migration of production as they have stated that yesterday. Every stock is like an animal, it changes character and this one has changed from euphoria to pessimism. I would only buy back on further falls, the update was disappointing - but my view is just one of a variety here. It was ramped up and now deramped, the chart will not turn quick imho, long term the business will dictate price. | che7win | |
17/1/2017 17:13 | To be a good liar you need a better memory than Potential has!! | susiebe | |
17/1/2017 17:10 | Strange claim to make potential when you have actually posted when you bought...and it wasn't at 80p.Anyway you have your motives for concealing the facts; I'll leave it at that. | longshanks | |
17/1/2017 16:46 | Good to know hottingup thanks for informing me! I stand corrected partially :) | frankwhite |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions